A5085337415- Asthma and respiratory diseases
- Lung Cancer Diagnosis and Treatment
- Inhalation and Respiratory Drug Delivery
- Chronic Obstructive Pulmonary Disease (COPD) Research
- Tracheal and airway disorders
- Anesthesia and Sedative Agents
- Management of metastatic bone disease
- Cancer Diagnosis and Treatment
- Respiratory Support and Mechanisms
- Head and Neck Cancer Studies
- Pulmonary Hypertension Research and Treatments
- Airway Management and Intubation Techniques
- Ultrasound in Clinical Applications
- Medical Imaging and Pathology Studies
- Pharmaceutical studies and practices
- Pediatric health and respiratory diseases
- Sarcoma Diagnosis and Treatment
- Allergic Rhinitis and Sensitization
- Pancreatic and Hepatic Oncology Research
- Respiratory and Cough-Related Research
Hospital Clínico Universitario de Valladolid
2017-2022
Catholic University of Ávila
2020-2022
Hospital Nuestra Señora de Alarcos
2020
Reslizumab is an anti-interleukin 5 monoclonal antibody that has demonstrated to reduce the risk of severe exacerbations and improve symptoms, lung function, quality life in randomized controlled trials included patients with eosinophilic uncontrolled asthma (SEUA) a history exacerbations.The aim present study was evaluate effectiveness add-on reslizumab cohort SEUA under real-life conditions.This multi-centre, retrospective, subjects treated 44 units throughout Spain. Eligible were those...
<b>Introduction:</b> Adequate adherence to non-invasive mechanical ventilation(NIMV)reflects functional and clinical improvement in patients, being sometimes a target difficult achieve. Our aim is identify factors related with better compliance(≥4h/night)and which patients present more long-term NIMV therapy order get higher quality treatment. <b>Methods:</b> Retrospective study of 559 indicate due different respiratory diseases. We analysed patient´s own factors(age, sex, disease)and...
Resection lung surgery-RLS is still the only curative treatment for cancer (LC) in early stage. Current ERS/ESTS guidelines recommend performing CPET patients with FEV1 or DLCO<80% to prevent postoperative complications <b>Objectives:</b> To assess performed our center undergoing RLS and determine if it´s really decisive therapeutic management <b>Methods:</b> We retrospectively studied between 2014-2016 LC proposed surgery. Indications, results, functional parameters, surgical procedures...
<b>Introduction:</b> Endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA) -A- has almost replaced conventional (TBNA) -B-. However, A requires from expensive equipment, a minimum volume of activity and specific training, thus its accessibility is limited. The aim our study was to assess the diagnostic value in patients submitted hospital perform B. Objetives methods. We performed prospective mediastinal pathology detected by computerized tomography with ambulatory...
Sedation improves patient and bronchoscopist's satisfaction, allowing complex procedures to be performed satisfactorily with good tolerance. However, it requires specific training. Our center recently incorporated deep sedation (SP) propofol (P) using TCI. We consider mandatory compare its safety profile our gold standard -GS- until then (administration of P in continuous perfusion after induction boluses) Observational study: Sample 1 (prospective cohort 20 bronchoscopies TCI system) sample...
We aimed to study the safety of propofol deep sedation managed by interventional pulmonologist in our centre Observational retrospective 900FB/EBUS between 2014-16. collected epidemiological variables, indications, monitoring parameters and diagnostic procedures(DP) Sedation complications: oxygen saturation(SO2)<90% or fall≥6%, systolic blood pressure(SBP)>160mmHg, SBP<90mmHg, heart rate(HR)>120bpm HR<60bpm Statistical analysis SPSSv22 900 procedures analyzed (75%ambulatory,...
Long- term domiciliary oxygen therapy (LTOT) is a therapeutic measure that has been shown to increase survival in patients with chronic obstructive pulmonary disease (COPD) and respiratory failure. It mandatory an annual re-evaluation of the clinican indication, order verify compliance evaluate clinical impact. A baseline gasometric assessment required rule out fictitious severe hypoxemia, which can cause up 30% unnecessary prescriptions during hospital discharge. The initial hypothesis...
<b>Introduction:</b> Reslizumab is a humanized monoclonal antibody against Interleukin-5 which administered every 4 weeks intravenously in patients with severe eosinophilic asthma. <b>Aims and Objetives:</b> Analyze changes lung function asthma symptoms. We perform measures before starting the treatment 28 days later. <b>Methods:</b> registered prospectively patient characteristics , FEV1 control using Asthma test (ACT) . record this data <b>Results:</b> 11 ( female ). Mean age 58,09 ± 12,5...
<b>Introduction:</b> EBUS usually takes longer than flexible bronchoscopy and can cause respiratory hemodynamic alterations. Sedation (S) improves tolerance but there is no standardisation. <b>Aim:</b> to analyse the variability of models S (MoS) supervised by a Bronchoscopist (B) in different hospitals Spain. <b>Methods:</b> A multicentre, prospective, observational study that included patients undergoing under B for 2 consecutive months 2018-2019 was conducted. Clinical variables, MoS...
<b>Aim:</b> To investigate whether the response to reslizumab is similar or different among patients not previously exposed these drugs (naïve) in with a prior failure (switchers). <b>Methods:</b> Multi-centre, retrospective, real-life study that included subjects severe uncontrolled eosinophilic asthma treated reslizumab. The main outcome measure was control, defined as absence of exacerbations, Asthma Control Test ≥ 20 and no maintenance oral corticosteroids (OCS). Follow-up: 52 weeks....